SG Americas Securities LLC Buys 96,593 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

SG Americas Securities LLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 110.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 184,196 shares of the medical equipment provider's stock after purchasing an additional 96,593 shares during the period. SG Americas Securities LLC owned approximately 0.09% of Zimmer Biomet worth $19,884,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in ZBH. Price T Rowe Associates Inc. MD lifted its holdings in Zimmer Biomet by 12.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock worth $1,404,638,000 after purchasing an additional 1,215,935 shares during the period. American Century Companies Inc. lifted its stake in shares of Zimmer Biomet by 12.6% in the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock worth $701,521,000 after acquiring an additional 722,041 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Zimmer Biomet by 6.7% in the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock valued at $365,163,000 after acquiring an additional 211,637 shares in the last quarter. Van ECK Associates Corp increased its stake in shares of Zimmer Biomet by 5.3% during the second quarter. Van ECK Associates Corp now owns 3,325,598 shares of the medical equipment provider's stock valued at $360,927,000 after acquiring an additional 167,038 shares during the period. Finally, Boston Partners raised its holdings in Zimmer Biomet by 26.3% during the first quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock worth $437,413,000 after purchasing an additional 691,191 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wolfe Research initiated coverage on Zimmer Biomet in a research note on Tuesday, September 10th. They set a "peer perform" rating for the company. BTIG Research lowered their target price on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a report on Thursday. UBS Group cut their price target on shares of Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating for the company in a report on Thursday, August 8th. Citigroup reduced their price objective on shares of Zimmer Biomet from $134.00 to $120.00 and set a "neutral" rating for the company in a research report on Wednesday, July 10th. Finally, Oppenheimer dropped their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus price target of $125.05.

Zimmer Biomet Stock Up 0.5 %

Zimmer Biomet stock traded up $0.49 during mid-day trading on Friday, hitting $104.68. The company's stock had a trading volume of 1,449,214 shares, compared to its average volume of 1,497,624. The firm's 50 day moving average is $109.19 and its 200 day moving average is $114.07. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 0.63. The company has a market cap of $21.54 billion, a PE ratio of 22.66, a price-to-earnings-growth ratio of 1.94 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.02. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company's revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.82 EPS. On average, analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet's payout ratio is currently 20.78%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.